Antidepressant Study Needs Mexican Volunteers
Posted on: Thursday, 6 March 2003, 06:00 CST
Antidepressant Study Needs Mexican Volunteers
Source: HealthScoutNews
People of Mexican origin are needed as volunteers for a depression study being conducted by scientists at the UCLA Neuropsychiatric Institute.
The study will apply information from the Human Genome Project to understand which antidepressant medications work best for people of that ethnic group who suffer from major clinical depression.
The multi-center project will examine the DNA of each volunteer and examine how genetic differences affect antidepressant drug response.
The study plan is to enroll 140 people a year for five years. Volunteers must be between 18 and 70 years old, have at least three of four Mexican-born grandparents, pass a physical exam and meet criteria for major depression after having a psychiatric interview.
The UCLA researchers will not ask about volunteers' insurance or citizenship status.
People with medical problems or other kinds of psychiatric problems such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or alcohol/drug abuse are not eligible for this study.
Volunteers will be randomly assigned to one of two groups. They'll receive 11 weeks of treatment with either Prozac or Norpramine. Both drugs are approved by the U.S. Food and Drug Administration for treatment of depression.
For more information, call UCLA research coordinator Gabriela Marquez at 310-825-6677. You can also email her at GMarquez@mednet.ucla.edu or go to the Web site.
More information
Here's where you can learn more about depression.
----
More news from the world's of science, space, and technology from RedNova
Related Articles
- Medicare Prescription Drug Plans Not Fully Compliant With Federal Regulations, According to Tufts Center for the Study of Drug Development
- Drug Makers Fail to Begin 71% of Promised Studies of Drugs Already Approved for the Market
- European Union Meeting Performance Goals for New Drug Review, but Lags Behind U.S. In New Drug Availability, According to Tufts Center for the Study of Drug Development
- Despite Development Challenges, Drug Developers Have Reason to Be Optimistic, According to Tufts Center for the Study of Drug Development
- Big Pharma May Be Emerging From R&Amp;D Productivity Doldrums, According to the Tufts Center for the Study of Drug Development
- Clinical Study of Drug-Free Psoriasis Treatment Under Way
- After Years of Declining R&D Productivity, Drug Development Is Poised to Take Off, According to Tufts Center for the Study of Drug Development
- New Drugs Are Taking Longer to Bring to Market in the U.S., According to Tufts Center for the Study of Drug Development
- No Link Between Drug Safety in U.S. And Approval Speed, According to Tufts Center for the Study of Drug Development
- ZymoGenetics Presents Results of Healthy Volunteer Study With TACI-Ig at 4th International Congress on Autoimmunity
 |
 |
User Comments (0)
RSS Feeds